Zurcher Kantonalbank Zurich Cantonalbank Boosts Stake in DaVita Inc. (NYSE:DVA)

Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in shares of DaVita Inc. (NYSE:DVA) by 22.3% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 114,166 shares of the company’s stock after buying an additional 20,782 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank owned about 0.14% of DaVita worth $18,715,000 at the end of the most recent reporting period.

Other hedge funds have also recently modified their holdings of the company. Transcendent Capital Group LLC purchased a new position in DaVita during the 3rd quarter valued at $25,000. Blue Trust Inc. lifted its position in shares of DaVita by 58.6% during the second quarter. Blue Trust Inc. now owns 211 shares of the company’s stock worth $29,000 after purchasing an additional 78 shares during the last quarter. Family Firm Inc. purchased a new stake in shares of DaVita during the second quarter valued at $43,000. Versant Capital Management Inc grew its holdings in shares of DaVita by 90.6% in the second quarter. Versant Capital Management Inc now owns 326 shares of the company’s stock worth $45,000 after purchasing an additional 155 shares during the last quarter. Finally, Friedenthal Financial purchased a new position in DaVita in the 2nd quarter worth about $48,000. Institutional investors own 90.12% of the company’s stock.

Insider Buying and Selling at DaVita

In other DaVita news, CEO Javier Rodriguez sold 9,881 shares of the stock in a transaction dated Friday, September 13th. The stock was sold at an average price of $162.85, for a total value of $1,609,120.85. Following the completion of the sale, the chief executive officer now directly owns 887,835 shares in the company, valued at approximately $144,583,929.75. This trade represents a 1.10 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. 2.00% of the stock is owned by insiders.

DaVita Trading Up 0.6 %

Shares of NYSE:DVA opened at $166.57 on Friday. The company has a current ratio of 1.37, a quick ratio of 1.33 and a debt-to-equity ratio of 15.78. The company has a market capitalization of $13.66 billion, a PE ratio of 17.97, a P/E/G ratio of 0.93 and a beta of 0.89. DaVita Inc. has a 12-month low of $99.18 and a 12-month high of $169.51. The business’s fifty day simple moving average is $158.52 and its 200-day simple moving average is $149.10.

DaVita (NYSE:DVA) last announced its earnings results on Tuesday, October 29th. The company reported $2.59 EPS for the quarter, missing analysts’ consensus estimates of $2.76 by ($0.17). DaVita had a return on equity of 88.18% and a net margin of 6.53%. The firm had revenue of $3.26 billion during the quarter, compared to the consensus estimate of $3.25 billion. During the same quarter in the prior year, the firm posted $2.85 earnings per share. The business’s revenue for the quarter was up 4.6% compared to the same quarter last year. As a group, equities research analysts predict that DaVita Inc. will post 9.71 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts have recently commented on the stock. UBS Group raised their target price on shares of DaVita from $169.00 to $175.00 and gave the stock a “buy” rating in a research report on Thursday, August 8th. Bank of America raised their price objective on DaVita from $139.00 to $145.00 and gave the stock an “underperform” rating in a report on Wednesday, August 7th. Barclays upped their target price on DaVita from $150.00 to $164.00 and gave the stock an “equal weight” rating in a report on Thursday, October 31st. Finally, Truist Financial raised their price target on DaVita from $165.00 to $175.00 and gave the company a “hold” rating in a research note on Monday, October 7th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and two have issued a buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $161.80.

DaVita Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.